Abstract
BackgroundPrevious neurocognitive assessments in non-central nervous system cancers highlight the high incidence of neurocognitive dysfunction in this study population. However, there have been few studies exploring neurocognitive dysfunction induced by chemotherapy in gynecological cancer patients. This prospective longitudinal study was conducted to assess neurocognitive functioning and functional brain networks in Chinese gynecological cancer patients pre- and post-chemotherapy, while additionally including age-matched healthy subjects as the control group.MethodsAll research participants were evaluated using a resting-state functional magnetic resonance imaging and neurocognition assessment. Behavioral data were conducted using SPSS for descriptive statistics, correlation and comparison analyses. Preprocessing of MRI (Magnetic Resonance Imaging) data and network analyses were performed using GRETNA (Graph Theoretical Network Analysis).ResultsA total of 40 subjects joined this study, with 20 subjects in each group. With the exception of the mean of psychomotor speed, there was no significant difference pre-chemotherapy between patients and healthy controls in neurocognitive test mean scores (Ps > 0.05). During the post-chemotherapy assessment, there were significant differences in the mean scores of neurocognitive tests (including Digit Span tests, verbal memory, immediate recall, delayed recall, and information processing speed tests) (all Ps < 0 .05). Longitudinal graph analysis revealed statistically significant differences in the patient group, with significant decreases in both local efficiency (P < 0.01) and global efficiency (P = 0.04). Lower raw TMT-A scores were significantly associated with lower local efficiency (r = 0.37, P = 0.03). Lower verbal memory scores were statistically significant and associated with lower global efficiency (r = 0.54, P = 0.02) in the patient group, but not in the healthy control group.ConclusionsThis study found that the risk of brain function and neurocognitive changes following chemotherapy could potentially guide patients in making appropriate treatment decisions, and this study may identify a cohort that could be suited for study of an intervention.
Highlights
Previous neurocognitive assessments in non-central nervous system cancers highlight the high incidence of neurocognitive dysfunction in this study population
Neurocognitive function of cancer patients compared to healthy controls As illustrated in Table 2, with the exception of information processing speed, there was no significant difference at T1 in the neurocognitive test mean scores between patients and healthy controls (Ps > 0.05)
There was a significant difference in neurocognitive test scores, at T2
Summary
Previous neurocognitive assessments in non-central nervous system cancers highlight the high incidence of neurocognitive dysfunction in this study population. Neurocognitive dysfunctions may affect executive function, psychomotor speed, attention and memory [3] This can interfere with gynecological cancer patients’ capacity to accomplish activities of daily living, as well as with social and occupational functioning, leading to lower quality of life [2, 4, 5]. While multiple neuroimaging studies have demonstrated structural and functional brain differences between cancer patients and healthy controls [9], structural changes in the brain cannot serve as a prompt or reliable biomarker for early diagnosis of treatment-induced neurocognitive disorders [10], as abnormalities in brain function usually appear before alterations in brain structure and clinical performance [11]. Detecting alterations in structural or functional brain networks might provide an earlier biomarker for neurocognitive dysfunction diagnosis [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
